Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
Rhea-AI Summary
Cellipont Bioservices and Ernexa Therapeutics (Nasdaq: ERNA) announced a collaboration on Oct 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, into clinical manufacturing and trials. The agreement covers Engineering, Differentiation, and Production (EDP) activities and cGMP development and scale-up of the ERNA-101 manufacturing process.
ERNA-101 is an off-the-shelf iMSC therapy designed to reprogram immunologically "cold" tumors to "hot" ones; preclinical data were presented at AACR and ASCO. The partnership targets translating preclinical promise into a clinically viable therapy.
Positive
- None.
Negative
- None.
News Market Reaction 20 Alerts
On the day this news was published, ERNA gained 40.80%, reflecting a significant positive market reaction. Argus tracked a peak move of +102.3% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $20M at that time. Trading volume was exceptionally heavy at 4144.6x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
"We are pleased to collaborate with Ernexa Therapeutics as they advance a bold and highly differentiated approach to treating cancer," said Darren Head, CEO of Cellipont Bioservices. "Supporting the development of synthetic, allogeneic iMSC therapies like ERNA-101 aligns with our commitment to enabling scientific innovation through collaborative, high-quality cell therapy manufacturing."
"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy," said Sanjeev Luther, President and CEO of Ernexa Therapeutics. "This collaboration marks an important milestone in advancing our iMSC platform, which we believe has the potential to reshape the treatment landscape for patients with advanced solid tumors."
Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). iMSC is a more specialized type of stem cell that has a unique ability to migrate toward tumors. Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting. ERNA-101 is Ernexa's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells.
In preclinical studies, presented at this year's AACR and ASCO annual meetings, ERNA-101 has shown the potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth. The Cellipont partnership will support the current Good Manufacturing Practice (cGMP) development and scale-up of the ERNA-101 manufacturing process in preparation for upcoming clinical trials.
About Cellipont
Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve. To learn more, visit www.cellipont.com and follow us on LinkedIn.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company's initial focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit www.ernexatx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cellipont-bioservices-and-ernexa-therapeutics-enter-cell-therapy-manufacturing-partnership-to-advance-erna-101-toward-clinical-trials-in-ovarian-cancer-302597673.html
SOURCE Cellipont Bioservices
FAQ
What did Ernexa (ERNA) announce on October 29, 2025 about ERNA-101?
How will the Cellipont partnership affect ERNA-101's manufacturing for ERNA (Nasdaq: ERNA)?
What is ERNA-101 and what indication is Ernexa targeting with ERNA (ERNA)?
Did Ernexa present ERNA-101 data before the Cellipont collaboration?
Will ERNA-101 be an off-the-shelf therapy for ERNA shareholders?
Does the October 29, 2025 announcement provide a clinical trial start date or financial terms for ERNA (ERNA)?
